Volume 9, Issue 19, (October 1999)

Slides:



Advertisements
Similar presentations
Reminders Midterm test on Tuesday Review session Saturday 4-6 PM, here. Reading: Chapters 3, 5, 6,
Advertisements

Cell-Mediated Cytotoxic Responses
Lessons from Hereditary Colorectal Cancer
Section 1 General Features of the Immune System
Innate immunity Part Ⅰ overview of innate immunity Part Ⅱ innate immune cells Part Ⅲ functions of innate immunity.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Natural Killer Cells:
HOST DEFENCE AGAINST TUMORS:
Natural Killer Cells Philipp Eissmann, Imperial College London, UK
Tumour immunology: T cells work together to fight cancer
CELL-MEDIATED IMMUNITY RAHUL KUMAR LOHANA 2K16/MB/50 INSTITUTE OF MICROBIOLOGY UNIVERSITY OF SINDH, JAMSHORO.
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Immunotherapy for Pediatric Cancer
T-Cell Immunity in Acute Coronary Syndromes
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect by Sherif S. Farag, Todd A. Fehniger, Loredana Ruggeri, Andrea.
Volume 8, Issue 20, (October 1998)
Michael W.M. Kühn, Scott A. Armstrong  Cancer Cell 
Volume 7, Issue 6, Pages (December 1997)
Isabel Barao, William J Murphy 
Cell signaling and cancer
Colorectal cancer vaccines: Principles, results, and perspectives
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Michael W.M. Kühn, Scott A. Armstrong  Cancer Cell 
A Molecular Warhead and Its Target
Why natural killer cells are not enough: a further understanding of killer immunoglobulin- like receptor and human leukocyte antigen  Diana Alecsandru,
Biology of the immunomodulatory molecule HLA-G in human liver diseases
Strength in Numbers: Visualizing CTL-Mediated Killing In Vivo
A Nuclear Strike against Listeria— The Evolving Life of LXR
Shannon M. Kahan, Allan J. Zajac  Immunity 
Human NK Cell Education by Inhibitory Receptors for MHC Class I
Volume 45, Issue 4, Pages (October 2006)
Maternal allo-recognition of the fetus
Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy  Steven G. Deeks, Bruce D. Walker 
Dendritic Cells Cell Volume 106, Issue 3, Pages (August 2001)
Jeffrey S Miller  Experimental Hematology 
Volume 84, Issue 2, Pages (August 2013)
Mechanism of CTLA-4-induced immunosuppression.
Increased frequency of human leukocyte antigen–E inhibitory receptor CD94/NKG2A– expressing peritoneal natural killer cells in patients with endometriosis 
Steroid hormones: Interactions with membrane-bound receptors
Volume 10, Issue 6, Pages (June 1999)
Antigen Presentation: Kissing cousins exchange CLIP
A View to Natural Killer Cells in Hepatitis C
Old Meets New: The Interaction Between Innate and Adaptive Immunity
Antigen-Presenting Cells: Professionals and amateurs
Volume 17, Issue 9, Pages (November 2016)
Volume 8, Issue 3, Pages R73-R75 (January 1998)
Deborah N. Burshtyn, Jiyeon Shin, Christopher Stebbins, Eric O. Long 
Volume 143, Issue 1, Pages (July 2012)
Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical.
HIV and HLA Class I: An Evolving Relationship
Volume 8, Issue 16, Pages R551-R553 (July 1998)
The Binding Site of NK Receptors on HLA-C Molecules
T-Cell Immunity in Acute Coronary Syndromes
Apoptosis Cell Volume 108, Issue 2, Pages (January 2002)
Natural Killer Cell Education and Tolerance
Tetsuo Takehara, Norio Hayashi 
Volume 24, Issue 14, Pages R658-R659 (July 2014)
The Platelet as a Model for Chemical Genetics
Therapy of Alopecia Areata: On the Cusp and in the Future
Releasing the Brakes on Cancer Immunotherapy
Vaccines for Lung Cancer
T cells and T-cell receptors in acute renal failure
Volume 12, Issue 6, Pages (June 2000)
Natural killer cell biology: An update and future directions
Volume 163, Issue 2, (October 2015)
Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)
Ibrutinib Treatment of CLL: The Cancer Fights Back
HIV and Chemokine Binding to Red Blood Cells—DARC Matters
André Veillette, Zhongjun Dong, Sylvain Latour  Immunity 
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Presentation transcript:

Volume 9, Issue 19, (October 1999) Natural killer cells  Clair M Gardiner  Current Biology  Volume 9, Issue 19, (October 1999) DOI: 10.1016/S0960-9822(99)80464-3

Figure 1 (a) A healthy cell expresses class I MHC molecules at its surface (represented here by the human MHC molecules HLA-C and HLA-E). These interact with receptors (represented here by human KIR2D and CD94–NKG2a) on the NK cell surface and transmit an inhibitory signal to the NK cell, thus sparing the healthy cell from lysis. The signal peptide (red) of classical MHC class I allows HLA-E expression on the cell surface. (b) In a target cell (a virally infected or cancerous cell) class I MHC may be no longer expressed at the surface. This cell therefore does not inhibit NK cells and is killed. (Activating signals are less well understood and are not shown.) Current Biology 1999 9, DOI: (10.1016/S0960-9822(99)80464-3)